Additional evidence highlights that the anti-tumour effects of YM155 are not solely mediated by its modulation of Survivin, but also via its transcriptional downregulation of MCL-1 [141, 147, 148] and induction of DNA damage [148, 149]. The gene discussed is MCL1; the disease is neoplasm.